Clinical Trial Update: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating the combination of pertuzumab, trastuzumab, hyaluronidase-zzxf, and enzalutamide for metastatic castration-resistant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Hyaluronidase-zzxf (hyaluronidase)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Status: COMPLETED